PBDF investment portfolio

OGI has made several PBDF investments over the past few years, including:

2012

Rna Diagnostics Inc, an early stage molecular diagnostics company developing assays aimed at assisting in the management of cancer chemotherapy.  The company will use the PBDF investment to further develop and validate their lead product, the RNA Disruption Assay™ (RDA™).  This assay is designed to monitor a patient’s response to chemotherapy earlier in treatment than current methods, and has the potential to be a valuable tool in terms of helping provide a personalized approach to chemotherapy management.

Read the OGI Press Release here.

Tissue Regeneration Therapeutics (TRT), is a start-up company that is developing umbilical stem cell-based treatments.  TRT will use the PBDF investment to conduct proteomic and transcriptomic analyses to further understand their mesenchymal stem cells. These studies will provide valuable information needed for regulatory approval to conduct human clinical trials and further differentiate their product from those of competitors.

Read the OGI Press Release here.

A research team at the University of Toronto is validating a novel protein interaction technology.  Utilizing the PBDF funding, the team will conduct development and validation necessary to make this assay commercially viable.  Once on the market, this tool will expand the resources available to researchers and companies developing new therapeutics.

Read the OGI Press Release here.

2011

A University of Toronto-based research effort developing innovative methods around an emerging class of therapeutics called macrocycles.  The team has developed a novel and effective process for making linear peptides circular.  The PBDF funding, as well as support from MaRS Innovation, will allow the team to further their efforts, including building a compound library and testing for important properties such as cell permeability and stability. 

Read the OGI Press Release here.

2010

ArcticDx, Inc, a Toronto-based company that has developed a genetic test, Macula Risk®, to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals.  ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

Read the OGI Press Release here.

2010

InDanio, an early-stage drug discovery and development company with a novel and unique screening system for the complete human nuclear hormone receptor (NR) family, using fluorescent tags attached to copies of human genes in living zebrafish embryos to identify and localize functioning individual NRs.  The screening system can be used to both characterize certain receptors as potential targets for drug discovery and to identify and refine potential new drugs that target NR proteins.

Read the OGI Press Release here.

2009

A joint effort by researchers at The Hospital for Sick Children and the University Health Network to develop a test, based on the genetic make-up of the potential donor and recipient, to help predict the outcomes of hematopoietic stem cell transplants, commonly referred to as bone marrow transplants.   This prognostic test would aim to predict and therefore decrease complications that can occur in transplant patients including transplant failure, graft versus host disease and others. 

Read the OGI News announcement here.

2009

A research effort based at the University of Guelph that is developing a set of genetic markers that can be used to monitor a marker-assisted selection breeding program to produce pigs that are free of boar taint, an undesirable odour or taste that is sometimes evident in pork products.  This has the potential to enable their industry partner and other breeding companies to produce more marketable pig lines.  

Read the OGI News announcement here

2009

Cytognomix, a start-up biotech company based in London, Ontario, is developing novel cytogenetic, single copy DNA probes that are smaller and more densely distributed across the genome than probes that are currently commercially available.  The probes will be designed to specifically detect individual chromosomal abnormalities such as those that underlie many diseases.

Read the OGI News announcement here

Read more about Cytognomix here.

2008

A joint effort by researchers at the Biodiversity Institute of Ontario (BIO, University of Guelph) and Toronto-based industry partner Safeguard Biosystems to develop a point-of-contact, DNA barcode-based assay that will differentiate between groups of animal species in random samples of plant and animal foods.

Read the OGI News announcement here.

Read more about the Barcode of Life project here.

2006

Ontario-based Amorfix Life Sciences Inc. is using molecular and proteomic techniques to develop a blood test for Alzheimer's disease. The company has shown that its test can detect aggregated protein (amyloid) in femtogram quantities (ten parts per trillion) when it is spiked into plasma or cerebral spinal fluid. The diagnostic assay is currently being tested in patient samples.

Read more about the assay here.

Read more about Amorfix here.

2005

A collaborative project between University of Toronto researchers and an international industry partner to develop and commercialize a device for use in yeast genomics and proteomics. The robotic device will allow higher-density replication of yeast colonies.

2004

A joint effort by scientists at McMaster University, the University of Waterloo, and Performance Plants, an agricultural biotechnology company based in Kingston, to develop transgenic plants with enhanced agronomics traits. This academic group and the company have formed a long-term collaborative relationship.

Read more about Performance Plants here.

2004

Researchers at the Natural Resources Canada Great Lakes Forestry Centre (Sault Ste. Marie) for a project that aims to develop a virus to control an insect that causes hundreds of millions of dollars of damage to crops annually. The researchers continue to work with international experts on this biocontrol agent.